Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Tango Therapeutics (TNGX) over the last 4 years, with Dec 2024 value amounting to -$1.19.

  • Tango Therapeutics' EPS (Weighted Average and Diluted) rose 148.15% to $0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.92, marking a year-over-year increase of 20.69%. This contributed to the annual value of -$1.19 for FY2024, which is 10.19% down from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' EPS (Weighted Average and Diluted) is -$1.19, which was down 10.19% from -$1.08 recorded in FY2023.
  • Tango Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.94 during FY2021, with a 5-year trough of -$1.23 in FY2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.17, with a median of -$1.19 in 2024.
  • As far as peak fluctuations go, Tango Therapeutics' EPS (Weighted Average and Diluted) crashed by 30.85% in 2022, and later increased by 12.20% in 2023.
  • Tango Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.94 in 2021, then slumped by 30.85% to -$1.23 in 2022, then increased by 12.20% to -$1.08 in 2023, then decreased by 10.19% to -$1.19 in 2024.